The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Codiak disavows any obligation to update the information contained in such press releases after the date of their issuance.

April 1, 2019
Development of the engEx™ Platform for Engineered Exosomes and Therapeutic Potential of Codiak’s exoSTING Highlighted at the 2019 American Association for Cancer Research Annual Meeting
February 20, 2019
Codiak BioSciences Names Andrea DiFabio Chief Legal Officer
January 3, 2019
Jazz Pharmaceuticals and Codiak BioSciences Announce Strategic Collaboration to Research, Develop and Commercialize Engineered Exosomes to Create Therapies for Hard-to-Treat Cancers
November 6, 2018
Codiak BioSciences Presents First Data on exoSTING – A Novel Engineered Exosome Therapeutic Targeting Checkpoint Refractory Tumors at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
September 11, 2018
Codiak BioSciences Names Robert M. Brenner, M.D. Executive Vice President, Research and Development
June 4, 2018
Codiak BioSciences Names Richard Brudnick Chief Business Officer and Head of Strategy
December 15, 2017
Codiak BioSciences Closes $76.5 Million Series C Financing
June 7, 2017
Potential Therapeutic Use of Exosomes Reported in NATURE
October 13, 2016
Codiak BioSciences Names Benny Sorensen, M.D., Ph.D., Vice President and Head of Clinical Development
May 17, 2016
Codiak BioSciences Names Jan Lötvall, M.D., Ph.D., Chief Scientist
January 26, 2016
Codiak BioSciences Closes $61 Million Series B Financing
January 5, 2016
Codiak BioSciences Names First Members of Executive Team
November 17, 2015
ARCH Venture Partners, Flagship Ventures and MD Anderson Collaborate to Launch Codiak BioSciences

Media Contact:

Lindy Devereux